Amylyx director granted 24,372 stock options
Amylyx Pharmaceuticals director Paul R. Fonteyne received a grant of stock options covering 24,372 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Amylyx Pharmaceuticals director Paul R. Fonteyne received a grant of stock options covering 24,372 shares of common stock. The options have an exercise price of $14.31 per share and were awarded at no cost to him as compensation.
These options vest in full on the earlier of June 4, 2027 or the date of the next annual meeting, as long as he continues serving the company through that date. After this grant, he holds 24,372 stock options directly.
Insider Trade Summary
Grant/Award: 24,372 shares
Grant/Award
1 txn
Insider
FONTEYNE PAUL R.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 24,372 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 24,372 contracts (Direct)
Footnotes (1)
- F1. The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Key Figures
Stock options granted: 24,372 options
Exercise price: $14.31 per share
Post-transaction holdings: 24,372 options
+2 more
5 metrics
Stock options granted
24,372 options
Grant to director Paul R. Fonteyne
Exercise price
$14.31 per share
Strike price for granted options
Post-transaction holdings
24,372 options
Derivative securities following transaction
Option expiration
June 3, 2036
Expiration date of stock options
Vesting date
June 4, 2027 or next annual meeting
Earlier date determines full vesting
Key Terms
Stock Option (right to buy), exercise price, expiration date, vest in full, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price": "14.3100""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2036-06-03T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest in full financial
"The shares subject to this option shall vest in full upon the earlier of"
annual meeting financial
"or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Amylyx Pharmaceuticals (AMLX) disclose about Paul R. Fonteyne in this Form 4?
Amylyx Pharmaceuticals reported that director Paul R. Fonteyne received a grant of stock options for 24,372 shares of common stock. The filing shows this as a compensation-related award rather than an open-market purchase or sale of existing shares.
How many Amylyx (AMLX) stock options were granted to Paul R. Fonteyne and at what price?
Paul R. Fonteyne was granted stock options covering 24,372 shares of Amylyx common stock. The options carry an exercise price of $14.31 per share, meaning he can buy the shares at that price once the options are vested and exercisable.
When do Paul R. Fonteyne’s Amylyx (AMLX) stock options vest according to the Form 4?
The options vest in full on the earlier of June 4, 2027 or the date of the next annual meeting. Vesting is conditioned on his continuous service to Amylyx through the applicable vesting date, as specified in the Form 4 footnote.
Is the Amylyx (AMLX) Form 4 for Paul R. Fonteyne a stock purchase or a grant?
The Form 4 reflects a grant of stock options, not a market purchase. It is coded as a grant or award acquisition, awarded at a price of $0.00 for the option itself, with an exercise price of $14.31 per underlying share.
How many Amylyx (AMLX) derivative securities does Paul R. Fonteyne hold after this Form 4 transaction?
Following the reported transaction, Paul R. Fonteyne holds 24,372 derivative securities in the form of stock options. These options each relate to one share of Amylyx common stock and are held directly, according to the ownership code in the filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates